Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on May 7, 2025
Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress
GlobeNewswire
·
May 7, 2025
Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this year New non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio …
scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025
GlobeNewswire
·
May 7, 2025
BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management …
Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
GlobeNewswire
·
May 7, 2025
SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration …
Anika to Participate in the Sidoti Virtual Investor Conference
GlobeNewswire
·
May 7, 2025
BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that …
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
GlobeNewswire
·
May 7, 2025
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment …
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 7, 2025
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose- …
OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System
GlobeNewswire
·
May 7, 2025
WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and …
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 7, 2025
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM …
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 7, 2025
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund …
Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025
GlobeNewswire
·
May 7, 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter …
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
GlobeNewswire
·
May 7, 2025
– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – sNDA for revumenib in R/R mNPM1 AML …
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
GlobeNewswire
·
May 7, 2025
NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s …
Cytokinetics to Hold Annual Meeting of Stockholders
GlobeNewswire
·
May 7, 2025
SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 14, 2025 at 10:00 AM Pacific Time at the Company’s headquarters, …
IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 7, 2025
Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 …
Best Probiotic For Women: Top Strains for Gut Health, Vaginal health & Constipation - Women Over 40,50,60 - Bioma
GlobeNewswire
·
May 7, 2025
Birštonas, May 07, 2025 (GLOBE NEWSWIRE) -- In this health-conscious era, choosing a good probiotic for women is no longer a supplement option—it's a lifestyle choice for women's health, digestion, and well-being; with so many probiotics on the market, …
The Best Place to Buy SARMs Online and OTC: Top SARM Brand & Company for Muscle Growth & Fat Loss - Safe Legal SARMS for Sale - CrazyBulk
GlobeNewswire
·
May 7, 2025
New York City, May 07, 2025 (GLOBE NEWSWIRE) -- The best place to buy SARMs is presented by CrazyBulk SARMs are the hottest trend in bodybuilding right now. Bodybuilders, weightlifters, and athletes everywhere are buying SARMs (Selective Androgen Receptor …
Best Legal Steroids for Muscle Growth & Testosterone Booster – Top Legal Supplements For Bulking, Cutting & Strength 2025 – By Wolfson Brands
GlobeNewswire
·
May 7, 2025
Glassgow, May 07, 2025 (GLOBE NEWSWIRE) -- Best Legal Steroids For Fastest Muscle Growth While the options in workout supplements are endless, here is a list of the five best options based on efficiency, results, price, and customer reviews. Read the basic …
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
GlobeNewswire
·
May 7, 2025
CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R…
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025
GlobeNewswire
·
May 7, 2025
VICTORIA, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to …
Yaqrit 的 HE 候选药物进入 3 期试验阶段并在 EASL 上展示了相关支持数据
GlobeNewswire
·
May 7, 2025
经 FDA 批准用于肝性脑病 3 期试验的一种改进型疾病分期工具，适用于静脉注射氨清除剂（YAQ006）。 口服氨清除剂（YAQ007）用于预防 HE 复发的剂量反应数据 氨清除剂作用机制的体内验证凸显与 TLR-4 拮抗剂（YAQ005）的潜在协同作用 伦敦, May 08, 2025 (GLOBE NEWSWIRE) -- Yaqrit 是一家聚焦临床后期阶段的公司，致力于开发治疗晚期肝病的救命疗法。本周，在 5 月 7 日至 10 日于阿姆斯特丹举行的欧洲肝脏研究协会（EASL …